Literature DB >> 8906814

Intracellular CD22 rapidly moves to the cell surface in a tyrosine kinase-dependent manner following antigen receptor stimulation.

N V Sherbina1, P S Linsley, S Myrdal, L S Grosmaire, J A Ledbetter, G L Schieven.   

Abstract

CD22 is a key accessory molecule for Ag receptor signaling in B cells that becomes tyrosine phosphorylated in the signaling process. CD22 associates with sIg and strongly amplifies sIg-induced signals. During B cell development, CD22 is initially expressed intracellularly, with surface expression appearing with IgD expression. We used confocal laser-scanning microscopy and flow cytometry to analyze CD22 translocation responses to signaling events. Cross-linking surface IgM (sIgM) induced rapid movement of CD22 to the cell surface in both Ramos and Daudi B cells, with a 50 to 100% increase in surface expression observed within 5 min of stimulation. The increase in CD22 surface expression was specific in that CD19 expression was not affected. Both cell surface and intracellular CD22 were directed toward the site of sIgM stimulation. Treatment with the phosphotyrosine phosphatase inhibitor bis(maltolato)oxovanadium(IV) also increased CD22 surface expression. The tyrosine kinase inhibitor tyrphostin A10 inhibited CD22 movement at concentrations that inhibited tyrosine phosphorylation of CD22 and other cellular proteins. In contrast to the B cell lines, mature peripheral blood B cells contained very little intracellular CD22 and showed no significant increase in surface expression following sIgM stimulation. The rapid directed movement of intracellular CD22 provides a new mechanism to dynamically regulate Ag receptor signaling, as well as CD22-mediated adhesion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8906814

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Nanoscale organization and dynamics of the siglec CD22 cooperate with the cytoskeleton in restraining BCR signalling.

Authors:  Francesca Gasparrini; Christoph Feest; Andreas Bruckbauer; Pieta K Mattila; Jennifer Müller; Lars Nitschke; Dennis Bray; Facundo D Batista
Journal:  EMBO J       Date:  2015-12-15       Impact factor: 11.598

2.  Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity.

Authors:  Xing Du; Richard Beers; David J Fitzgerald; Ira Pastan
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

3.  Sialic acid binding domains of CD22 are required for negative regulation of B cell receptor signaling.

Authors:  Lei Jin; Paul A McLean; Benjamin G Neel; Henry H Wortis
Journal:  J Exp Med       Date:  2002-05-06       Impact factor: 14.307

4.  Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T cells from cutaneous T cell lymphoma (CTCL) patients.

Authors:  Ieva Bagdonaite; Hans H Wandall; Ivan V Litvinov; Claudia Nastasi; Jürgen C Becker; Sally Dabelsteen; Carsten Geisler; Charlotte M Bonefeld; Qian Zhang; Mariusz A Wasik; Youwen Zhou; Denis Sasseville; Niels Ødum; Anders Woetmann
Journal:  Oncotarget       Date:  2015-06-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.